#United Kingdom #Piramal Pharma #Morpeth #Korsch X3 #Morpeth Site

Celebrating Two Decades of Innovation and Growth at Piramal Pharma Solutions

Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO), recently marked a significant milestone in its journey by celebrating the 20th anniversary of its pharmaceutical manufacturing site in Morpeth, UK. As part of this remarkable achievement, the company has made a substantial investment in a Korsch X3 tablet press, a cutting-edge piece of equipment that enhances its manufacturing capabilities.

The Korsch X3 is specifically designed to cater to the intricate demands of high-potency active pharmaceutical ingredients (HPAPIs), showcasing Piramal's commitment to meeting the evolving needs of the pharmaceutical industry. Equipped with a comprehensive containment system, this press operates at Band 5 level, ensuring the safe and secure production of highly active pharmaceutical products at both clinical and commercial scales.

This acquisition not only celebrates the successful operational history of the Morpeth facility but also reinforces its position as a leader in the field of pharmaceutical manufacturing. The introduction of the Korsch X3 comes at a time when there is an increasing demand for complex therapies, allowing Piramal to expand its capacity to manufacture tailored solutions for patients in need.

Innovative Features of the Korsch X3
The Korsch X3 is equipped with two customized turrets that facilitate the production of larger tablets up to 25mm, thereby broadening the array of formulations that the facility can produce. This adaptable press improves operational efficiency and enhances tablet durability while minimizing the risk of contamination. Unlike conventional tablet presses which require wide-open ingredient feeding, the Korsch X3 features a contained feeding system, which draws materials from storage bins and directs them through sanitized pathways directly into the production line.

Additionally, the Korsch X3 incorporates advanced safety features, including hygiene protocols to protect operators during the manufacturing process. The use of dual side hand passes, front hand passes, and a misting system to neutralize airborne contaminants post-production ensures a safe working environment, essential for handling toxic substances. A specialized training program was provided by Korsch for the Morpeth team, enabling them to operate the new machinery confidently and efficiently.

Statements from Leadership
Peter DeYoung, CEO of Piramal Global Pharma, expressed his pride over the recent acquisition. “This investment not only bolsters Morpeth's capability to produce high-potency tablets but also emphasizes our unwavering dedication to improving patient outcomes across various therapeutic areas, particularly in hormone production.” He underscored how the Korsch X3 aligns perfectly with the site’s 20-year legacy, heralding a future where Piramal can meet the needs of even more patients internationally.

As Piramal Pharma Solutions embarks on its next chapter, the integration of the Korsch X3 into its manufacturing process gives the Morpeth site an invaluable advantage in the pharmaceutical landscape. This combination of innovation and commitment to patient-centric solutions solidifies Piramal's standing as a leader in development and manufacturing.

About Piramal Pharma Solutions

Piramal Pharma Solutions is a renowned CDMO that provides integrated development and manufacturing services throughout the lifecycle of pharmaceutical products. With a global network of facilities across North America, Europe, and Asia, Piramal caters to a wide array of services including drug development, manufacturing of active pharmaceutical ingredients (APIs), clinical trial supply, and commercial availability of finished dosage forms. In addition to these core services, Piramal specializes in high-potency active pharmaceutical ingredients, advanced drug delivery systems, and biologics production, ensuring comprehensive support for clients in their drug development endeavors.

By investing in state-of-the-art technology like the Korsch X3, Piramal Pharma Solutions continues to pave the way for a future where patients worldwide have access to innovative therapies that improve and prolong lives.